Address
1100 Winter Street
Waltham, MA 02451
United States of America (the)
Phone
617 433 2605
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
July 30, 2020
| Name | Title | Pay | Year Born |
| Diana Brainard | Chief Executive Officer & Director | 373,042 | 1972 |
| Vikas Sinha | Chief Executive Officer, President, Chief Financial Officer & Director | 544,400 | 1963 |
| David L. Hallal | Executive Chairman of the Board | 200,000 | 1966 |
| Edward Miller | General Counsel & Secretary | 645,693 | 1965 |
| Brett R. Hagen | Chief Accounting Officer | 796,311 | 1973 |
| Cintia Piccina | Chief Commercial Officer | 0 | 1973 |
| Ann Leen | Chief Scientific Officer | 0 | 1977 |
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.